PF-07321332

• CAT Number: I034512
• CAS Number: 2628280-40-8
• Molecular Formula: C23H32F3N5O4
• Molecular Weight: 499.53
• Purity: 98%
• Synonyms: PF-07321332; PF 07321332; PF07321332
• Solubility: To be determined
• Storage: Store at -20°C
• IUPAC Name: (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
• InChI: InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1
• InChIKey: LIENCHBZNNMNKG-OJFNHCPVSA-N
• SMILES: CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C

PF-07321332（Cat No.:I034512）, also known as nirmatrelvir, is an investigational antiviral drug developed by Pfizer for the treatment of COVID-19. It is an orally administered protease inhibitor that targets the viral 3CL protease (also known as Mpro). By inhibiting the activity of this protease, PF-07321332 aims to prevent viral replication and limit the spread of SARS-CoV-2, the virus responsible for COVID-19. PF-07321332 has shown promising results in preclinical and clinical studies and is being evaluated for its efficacy and safety in treating COVID-19 patients.

Reference

https://cen.acs.org/acs-news/acs-meeting-news/Pfizer-unveils-oral-SARS-CoV/99/i13